Biomarkers Diagnostic Perspectives and Clinical Significance
Date: 07/26/2021 - 07/27/2021 | Dhaka , Bangladesh

A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment (www.nih.gov).

The Biomarkers Event 2021 will look into the perspectives defining the influence and significance of Biological indicators in Clinical Research, and Diagnostic Aspects and Therapy and Management for various disease indications, and the Translational Research adopted.

About Biomarkers Diagnostic Perspectives and Clinical Significance

Development of Therapeutics under the Clinical settings is the acceptable format of treatment for disease indications, and biological indicators being the validator.

A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment (www.nih.gov).

The Biomarkers Event 2021 will look into the perspectives defining the influence and significance of Biological indicators in Clinical Research, and Diagnostic Aspects and Therapy and Management for various disease indications, and the Translational Research adopted.

Biomarkers Event 2021 includes Keynote presentation, Oral Talks, Poster presentations, Product Development and Technology Presentations, Solution Provider and Vendor Presentations, along with Biomarkers Discovery and Development Market Insights Session covering the Market Leaders, KOLs, and other important stake holders in the Biomarker Research, Discovery and Development, covering key research areas in

Biomarker Discovery and Development, Biomarker Technologies, Clinical Biomarkers, Diagnostic and Prognostic Biomarkers, Digital Biomarkers, Genomic and Proteomic Biomarkers, Cancer and Immuno-Oncology Biomarkers, Cardiac Biomarkers, Neurological Biomarkers, Imaging and Radiological Biomarkers, Companion Diagnostics, Precision Medicine, Personalized Medicine, Biomarkers in Translational Medicine and Research, Development in Molecular Medicine and Biomarkers, Technological Implications and Regulatory Perspectives in Biomarker Discovery and Development.

Biomarkers Diagnostic Perspectives and Clinical Significance Sessions

Biomarker Discovery and Development

Biomarker Technologies

Clinical Biomarkers

Diagnostic and Prognostic Biomarkers

Digital Biomarkers

Genomic and Proteomic Biomarkers

Cancer and Immuno-Oncology Biomarkers

Cardiac Biomarkers

Neurological Biomarkers

Imaging and Radiological Biomarkers

Companion Diagnostics, Precision Medicine and Personalized Medicine

Biomarkers in Translational Medicine and Research

Development in Molecular Medicine and Biomarkers

Technological Implications and Regulatory Perspectives in Biomarker Discovery and Development



Market Overview

Biomarkers market majorly include the types and disease specific, wherein the former covers the Clinical, Diagnostics, Prognostics, Precision, Digital, Genomic and Imaging, and the latter covers disease area or indication specific such as Cancer and Immuno-Oncology, Cardiac, Neurological and Metabolic Biomarkers, and all the market players who study, develop, promote and partner into the research and application of Biomarkers Market Space. Clinical and Diagnostic Biomarkers holds a big share in the type segment with trending growth perspectives for Digital Biomarkers, while cancer and oncology is the largest in the segment of disease type.

Cancer Biomarkers Market is segmented based on cancer type, biomolecules, profiling technology and application. The type sub-segment include breast cancer, prostate cancer, lung cancer, colorectal cancer and stomach cancer. The biomolecules sub-segment include genetic, glycoprotein and protein biomarkers. Profiling technology sub-segment covers cytogenetic based tests, immunoassays, omic and imaging technologies. The application sub-segment includes clinical, drug discovery and development, diagnostics and prognostics.

Market Opportunities for Cancer Biomarkers is due to the technological advancements in genomic profiling and molecular targeted therapies which has opened the testing and regulatory perspectives of potential biomarkers and help drift the development of new biomarkers. Below listed are more Market Drivers for Cancer Biomarkers and the related market hurdles.

·         Understanding and accepted importance of biological and targeted drug therapies by regulatory bodies, but the price and timeline associated with the drug development and the safety and efficacy measures associated with the cancer therapy cumulates to the risk of failure or denial by regulatory bodies

·         Increase in acquisitions and collaborations with more players joining the market and new market explorations

·         Technological advancements have given the specificity and enough room for niche but potential segments like Digital Biomarkers


·         Expanding and Growing research with an increased disease population and high prevalence rate of cancer related disease conditions and disorders, but the costs associated with Sample Collection, Sample Storage, and sample processing in the Biomarker development value chain are always the game changer as it is an big additional cost to the total discovery and development costs

·         Increased and improved investment from public, government and private sectors

·         With more development in regulatory measures the number of clinical trials have increased, but this increase in trials for therapy development are subjected to strict regulatory rules and repayment policies

·         Expansion in application and product development segments such as personalized medicine, companion diagnostics and precision medicine

Key players in the Biomarker market space includes Abbott Laboratories, Agilent Technologies, Aushon Biosystem, Bio-Rad Laboratories, Eisai, Epistem, GE Healthcare, Roche Diagnostics, Siemens, Thermo Fisher Scientific, F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline, Novartis, Merck & Co, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Qiagen and Genomic Health.

Conference Schedule

Program Time Program Session
08:00 - 09:00 Registration
09:00 - 09:30 Opening Ceremony and Introduction
09:30 - 10:30 Keynote Session I
10:30 - 11:00 Refreshment Break
11:00 - 12:30 Keynote Session II
12:30 - 13:30 Lunch
13:30 - 15:00 Breakout Session I
15:00 - 15:30 Refreshment Break
15:30 - 18:00 Breakout Session II
Program Time Program Session
09:00 - 10:30 Keynote Session III
10:30 - 11:00 Refreshment Break
11:00 - 12:30 Breakout Session III
12:30 - 13:30 Lunch
13:30 - 15:00 Poster Presentations
15:00 - 15:30 Refreshment Break
15:30 - 17:30 Breakout Session IV
17:30 - 18:30 Closing Ceremony

Standard Registration

Academic

$ 0


Conference Material


Access to Exhibits poster and sessions


Lunch, tea / coffee breaks


Wifi in meeting rooms


Register

Industry

$ 0


Conference Material


Access to Exhibits poster and sessions


Lunch, tea / coffee breaks


Wifi in meeting rooms


Register

Delegate

$ 0


Conference Material


Access to Exhibits poster and sessions


Lunch, tea / coffee breaks


Wifi in meeting rooms


Register

Student

$ 0


Conference Material


Access to Exhibits poster and sessions


Lunch, tea / coffee breaks


Wifi in meeting rooms


Register